Saba Capital Management’s ProKidney PROK Stock Holding History

Saba Capital Management’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-215,476	Closed	-$2.14M	–	1146
2022 Q2	$2.14M	Hold	215,476	–	–	0.03%	658
2022 Q1	$2.13M	Sell	215,476 -34,737	-14%	-$343K	0.03%	581
2021 Q4	$2.48M	Hold	250,213	–	–	0.04%	492
2021 Q3	$2.45M	Buy	+250,213	New	+$2.46M	0.06%	339

Other funds holding PROK

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

MCM

Moore Capital Management New York $4.92B AUM 35.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Saba Capital Management's PROK Position: Q3 2022 in Review

Saba Capital Management sold out of ProKidney (PROK) in Q3 2022, closing a stake of 215,476 shares — an estimated $2.14M sold.

Saba Capital Management first reported a position in PROK in Q3 2021 and held it in 4 quarters. The position peaked at $2.48M in Q4 2021. 18 funds tracked by Wall St. Rank hold PROK as of Q3 2022.

Saba Capital Management reported no remaining ProKidney position as of Q3 2022 after selling out during the quarter.
Saba Capital Management sold 215,476 ProKidney shares in Q3 2022, an estimated $2.14M.
Saba Capital Management first reported a position in ProKidney in Q3 2021 and held it in 4 quarters.
Saba Capital Management's ProKidney position peaked at $2.48M in Q4 2021.
18 funds tracked by Wall St. Rank held ProKidney as of Q3 2022.

Based on Saba Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.